チューブリン修飾薬

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 複合免疫不全 combined immunodeficiencies
2. 分類不能型低ガンマグロブリン血症の病因 pathogenesis of common variable immunodeficiency
3. 小細胞肺癌の治療に対する実験的アプローチ experimental approaches to treatment for small cell lung cancer
4. プロゲステロン受容体モジュレーター（PRM）の薬理学および作用機序 pharmacology and mechanism of action of progesterone receptor modulators prms
5. 抗酸菌易感染性を示すメンデル型遺伝性疾患：概要 mendelian susceptibility to mycobacterial diseases an overview

English Journal

HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.

Pavan S1, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF.Author information 1Department of Oncology, University of Torino, School of Medicine, Torino, Italy; Laboratory of Cancer Genetics, Institute for Cancer Research at, Candiolo, Torino, Italy.AbstractThe hepatocyte growth factor (HGF) also known as scatter factor activates cancer cell invasion and metastasis. We show that in ovarian cancer cells HGF induced the phosphorylation of the small heat shock protein of 27 kDa (HSP27) by activating the p38MAPK. HSP27 is increased in many cancers at advanced stage including ovarian cancer and associated with cancer resistance to therapy and poor patients' survival. The phosphorylation of HSP27 regulates both its chaperone activity and its control of cytoskeletal stability. We show that HSP27 was necessary for the remodeling of actin filaments induced by HGF and that motility in vitro depended on the p38MAPK-MK2 axis. In vivo, HSP27 silencing impaired the ability of the highly metastatic, HGF-secreting ovarian cancer cells to give rise to spontaneous metastases. This was due to defective motility across the vessel wall and reduced growth. Indeed, HSP27 silencing impaired the ability of circulating ovarian cancer cells to home to the lungs and to form experimental hematogenous metastases and the capability of cancer cells to grow as subcutaneous xenografts. Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug. Altogether, these data show that the HSP27 is required for the proinvasive and prometastatic activity of HGF and suggest that HSP27 might be not only a marker of progression of ovarian cancer, but also a suitable target for therapy.
International journal of cancer. Journal international du cancer.Int J Cancer.2014 Mar 15;134(6):1289-99. doi: 10.1002/ijc.28464. Epub 2013 Sep 18.
The hepatocyte growth factor (HGF) also known as scatter factor activates cancer cell invasion and metastasis. We show that in ovarian cancer cells HGF induced the phosphorylation of the small heat shock protein of 27 kDa (HSP27) by activating the p38MAPK. HSP27 is increased in many cancers at advan
PMID 23996744

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I1, Tuxen MK, Nielsen DL.Author information 1Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: Iben.Kumler@regionh.dk.AbstractBACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15-20% of all breast cancers. Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adjuvant and metastatic settings. However, trastuzumab resistance is common and a major focus in the treatment of HER2-positive breast cancer has been developing therapeutic agents to either potentiate the effect of trastuzumab or to target cells which have become resistant to trastuzumab. The present review addresses efficacy and toxicity of dual targeting in HER2-positive breast cancer.
Cancer treatment reviews.Cancer Treat Rev.2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15-20% of all breast cancers. Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adju
PMID 24080156